OKYO Pharma Limited
OKYONASDAQHealthcareBiotechnology
Previous close
$1.54
+$0.02 · +1.32%
OKYO company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
44
Neutral
Sentiment
47
Mixed
Risk resilience
41
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteOKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- GB
- CEO
- Robert J. Dempsey
- Listed since
- May 17, 2022
- Employees
- 5
Market position
Day range
Current $1.54
52-week range
Current $1.54
- Open
- $1.52
- Previous close
- $1.52
- Volume
- 14.67K
- 0.17× average
- Average volume
- 87.07K
- Average daily volume
- Market cap
- 59.09M USD
- Beta
- 0.05
- Market reference 1
- 50-day average
- $1.554
- -0.90% below average
- 200-day average
- $1.7988
- -14.39% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 45.55M USD
- EV / EBITDA
- -5.38×
- Earnings yield
- -14.88%
- Free cash flow yield
- -9.88%
Profitability & efficiency
- Return on equity
- -72.55%
- Return on assets
- -42.67%
- Return on invested capital
- -68.91%
Financial health
- Current ratio
- 2.43×
- Altman Z-score
- -7.79
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cost of goods sold | 6.69M USD | 2.56K USD | 7.51M USD | 6.75M USD | 13K USD |
| Gross profit | −6.69M USD | −2.56K USD | −7.51M USD | −6.75M USD | −13K USD |
| Research and development | 1.81M USD | 2.25M USD | 8.24M USD | 6.34M USD | 1.61M USD |
| Selling, general, and administrative | — | 4.93M USD | — | 6.75M USD | 4.93M USD |
| Operating expenses | 1.81M USD | 7.19M USD | 8.24M USD | 6.34M USD | 6.22M USD |
| Interest income | 32.1K USD | 5.47K USD | — | — | — |
| Interest expense | 473.94K USD | 883.65K USD | 1.05M USD | 96.69K USD | — |
| Depreciation and amortization | 1.82K USD | 2.56K USD | 3.87K USD | 3.8K USD | 2.33K USD |
| Operating income | −8.5M USD | −7.19M USD | −15.75M USD | −13.09M USD | −6.23M USD |
| Net income | −8.95M USD | −4.71M USD | −16.83M USD | −13.27M USD | −5.43M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -0.24
- FY2026
- Latest fiscal-year revenue
- 0 USD
- FY2026
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$5.00
224.68% upsideRecent analyst actions
OKYO news
OKYO peers
Continue in GoAI
Research OKYOresearch.disclaimer